We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Crash diet

11 February 2013 By Quentin Webb

The Danish drugmaker lost about $14 bln in market value after U.S. regulators held off approving a new insulin treatment. As the world grows obese, the diabetes specialist should profit handsomely. But the shares look rich, even after the 13 pct markdown.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)